1
|
Vašíček J, Shehata M, Schnabl S, Hilgarth M, Hubmann R, Jäger U, Bauer M, Chrenek P. Critical assessment of the efficiency of CD34 and CD133 antibodies for enrichment of rabbit hematopoietic stem cells. Biotechnol Prog 2018; 34:1278-1289. [PMID: 29882300 DOI: 10.1002/btpr.2659] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2017] [Revised: 03/25/2018] [Indexed: 12/11/2022]
Abstract
Rabbits have many hereditary diseases common to humans and are therefore a valuable model for regenerative disease and hematopoietic stem cell (HSC) therapies. Currently, there is no substantial data on the isolation and/or enrichment of rabbit HSCs. This study was initiated to evaluate the efficiency of the commercially available anti-CD34 and anti-CD133 antibodies for the detection and potential enrichment of rabbit HSCs from peripheral blood. PBMCs from rabbit and human blood were labelled with different clones of anti-human CD34 monoclonal antibodies (AC136, 581, and 8G12) and rabbit polyclonal CD34 antibody (pCD34) and anti-human CD133 monoclonal antibodies (AC133 and 293C3). Flow cytometry showed a higher percentage of rabbit CD34+ cells labelled by AC136 in comparison to the clone 581 and pCD34 (P < 0.01). A higher percentage of rabbit CD133+ cells were also detected by 293C3 compared to the AC133 clone (P < 0.01). Therefore, AC136 clone was used for the indirect immunomagnetic enrichment of rabbit CD34+ cells using magnetic-activated cell sorting (MACS). The enrichment of the rabbit CD34+ cells after sorting was low in comparison to human samples (2.4% vs. 39.6%). PCR analyses confirmed the efficient enrichment of human CD34+ cells and the low expression of CD34 mRNA in rabbit positive fraction. In conclusion, the tested antibodies might be suitable for detection, but not for sorting the rabbit CD34+ HSCs and new specific anti-rabbit CD34 antibodies are needed for efficient enrichment of rabbit HSCs. © 2018 American Institute of Chemical Engineers Biotechnol. Prog., 2018 © 2018 American Institute of Chemical Engineers Biotechnol. Prog., 34:1278-1289, 2018.
Collapse
Affiliation(s)
- Jaromír Vašíček
- NAFC-Research Institute for Animal Production in Nitra, Institute of Farm Animal Genetics and Reproduction, Lužianky, Slovak Republic, Hlohovecká 2, 951 41.,Research Centre AgroBioTech, Slovak University of Agriculture, Tr. A. Hlinku 2, 949 76 Nitra, Slovak Republic.,Faculty of Biotechnology and Food Science, Department of Biochemistry and Biotechnology, Slovak University of Agriculture, Nitra, Tr A. Hlinku 2, 949 76, Slovak Republic
| | - Medhat Shehata
- Dept. of Internal Medicine I, Div. of Haematology and Haemostaseology, Comprehensive Cancer Centre Vienna, Drug and Target Screening Unit DTSU, Medical University of Vienna, Waehringer Guertel 18-20, Vienna, A-1090, Austria
| | - Susanne Schnabl
- Dept. of Internal Medicine I, Div. of Haematology and Haemostaseology, Comprehensive Cancer Centre Vienna, Drug and Target Screening Unit DTSU, Medical University of Vienna, Waehringer Guertel 18-20, Vienna, A-1090, Austria
| | - Martin Hilgarth
- Dept. of Internal Medicine I, Div. of Haematology and Haemostaseology, Comprehensive Cancer Centre Vienna, Drug and Target Screening Unit DTSU, Medical University of Vienna, Waehringer Guertel 18-20, Vienna, A-1090, Austria
| | - Rainer Hubmann
- Dept. of Internal Medicine I, Div. of Haematology and Haemostaseology, Comprehensive Cancer Centre Vienna, Drug and Target Screening Unit DTSU, Medical University of Vienna, Waehringer Guertel 18-20, Vienna, A-1090, Austria
| | - Ulrich Jäger
- Dept. of Internal Medicine I, Div. of Haematology and Haemostaseology, Comprehensive Cancer Centre Vienna, Drug and Target Screening Unit DTSU, Medical University of Vienna, Waehringer Guertel 18-20, Vienna, A-1090, Austria
| | - Miroslav Bauer
- NAFC-Research Institute for Animal Production in Nitra, Institute of Farm Animal Genetics and Reproduction, Lužianky, Slovak Republic, Hlohovecká 2, 951 41.,Faculty of Natural Sciences, Department of Botany and Genetics, Constantine the Philosopher University in Nitra, 949 74 Nitra, mládeže, Slovak Republic, Nábrežie 91
| | - Peter Chrenek
- NAFC-Research Institute for Animal Production in Nitra, Institute of Farm Animal Genetics and Reproduction, Lužianky, Slovak Republic, Hlohovecká 2, 951 41.,Faculty of Biotechnology and Food Science, Department of Biochemistry and Biotechnology, Slovak University of Agriculture, Nitra, Tr A. Hlinku 2, 949 76, Slovak Republic
| |
Collapse
|
4
|
Hou S, Li B, Wang L, Qian W, Zhang D, Hong X, Wang H, Guo Y. Humanization of an anti-CD34 monoclonal antibody by complementarity-determining region grafting based on computer-assisted molecular modelling. J Biochem 2008; 144:115-20. [PMID: 18424812 DOI: 10.1093/jb/mvn052] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
4C8 is a new mouse anti-human CD34 monoclonal antibody (mAb), which recognizes class II CD34 epitopes and can be used for clinical hematopoietic stem/progenitor cell selection. In an attempt to improve its safety profiles, we have developed a humanized antibody of 4C8 by complementarity-determining region (CDR) grafting method in this study. Using a molecular model of 4C8 built by computer-assisted homology modelling, framework region (FR) residues of potential importance to the antigen binding were identified. A humanized version of 4C8, denoted as h4C8, was generated by transferring these key murine FR residues onto a human antibody framework that was selected based on homology to the mouse antibody framework, together with the mouse CDR residues. The resultant humanized antibody was shown to possess antigen-binding affinity and specificity similar to that of the original murine antibody, suggesting that it might be an alternative to mouse anti-CD34 antibodies routinely used clinically.
Collapse
Affiliation(s)
- Sheng Hou
- International Joint Cancer Institute, Second Military Medical University, Shanghai 200433, People's Republic of China
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Qian W, Wang L, Li B, Wang H, Hou S, Hong X, Zhang D, Guo Y. Development of new versions of anti-human CD34 monoclonal antibodies with potentially reduced immunogenicity. Biochem Biophys Res Commun 2008; 367:497-502. [DOI: 10.1016/j.bbrc.2007.12.184] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2007] [Accepted: 12/28/2007] [Indexed: 10/22/2022]
|